Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Company Overview - Lyell Immunopharma is a clinical-stage T-cell reprogramming company focused on developing cell therapies for solid tumors and hematologic malignancies [3] - The company has three product candidates in or entering Phase 1 clinical development [3] - Lyell's proprietary technology addresses T-cell exhaustion and lack of durable stemness to improve clinical outcomes [3] - The company is headquartered in South San Francisco, California with additional facilities in Seattle and Bothell, Washington [3] Upcoming Event - Lyell's President & CEO, Lynn Seely, MD, will participate in a panel discussion on next-generation cell therapies in oncology at Goldman Sachs Cell Therapy Day on October 1, 2024, at 11:50 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible after the live event [2]